Imaxio Signs Option for License Agreement to Develop Veterinary Vaccines12 June 2013
FRANCE - Imaxio, a biopharmaceutical company specialized in vaccines and genomics, announced that it has signed a license option agreement with a major animal health laboratory, a top ten company globally in its sector. The aim of the agreement is to develop a number of veterinary vaccines using Imaxio's immuno-enhancing IMX313 technology.
The agreement grants the partner permission to carry out its own evaluation of Imaxio's IMX313 technology. Subject to the results of the evaluation it provides the option of a license agreement to use IMX313 in developing vaccines for a total of four animal health indications. The name of the partner and the technical and financial terms of the agreement are not disclosed.
Imaxio's proprietary antigen re-engineering technology, IMX313, is designed to enhance the immune response and, therefore, the effectiveness of vaccines with which it is combined. IMX313 offers significant potential as a solution to developing vaccines for major indications in response to the challenge posed by some human and animal health candidates which lack effectiveness.
"This new agreement with a major player in veterinary pharmacy is a further boost to our confidence in the IMX313 technology, following Imaxio signing the license option with Merial last December. The IMX313 technology is crucial to our continued in-house development of vaccines for tuberculosis, flu, staphylococcus aureus and veterinary cryptosporidiosis," said Alexandre Le Vert, chief executive officer of Imaxio. "We are delighted to have secured promising collaboration agreements with renowned academic and industrial partners. This enables us to promote the use of IMX313 in the development of vaccines and immunotherapies for use in additional indications. We are keen to build on our initial success and are therefore continuing to seek out potential partners."
|ThePigSite News Desk||Read more Merial News here|